open access
LYAR promotes the proliferation of non-small cell lung cancer and is associated with poor prognosis
Affiliations- Department of Cardiothoracic Surgery, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, 223800, Jiangsu, China
- Department of Thoracic Surgery, Nantong Tumor Hospital, Nantong, 226001, Jiangsu, China
- Department of Gastroenterology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, 223800, Jiangsu, China
- Department of Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
- Department of Neurosurgery, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, 223800, Jiangsu, China
open access
Abstract
Introduction. The aim of the study was to investigate the clinical significance of Ly-1 antibody reactive clone
(LYAR) in non-small-cell lung cancer (NSCLC).
Material and methods. The expressions of LYAR at the protein level in representative paired NSCLC tumor tissues and adjacent non-tumor tissues were measured by Western blot and immunohistochemistry. Kaplan-Meier method was used to calculate the survival curve of patients with NSCLC. Cell Counting Kit-8 assay and flow cytometry were used to estimate the cell proliferation and cell cycle, respectively. Terminal-deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay was performed to detect cell apoptosis.
Results. LYAR was dramatically overexpressed in NSCLC tissues which were closely related to the survival of patients with NSCLC. In clinical studies, the expression of LYAR was related to the clinical stage, histological differentiation, and Ki-67 expression. A positive correlation was found between LYAR and Ki-67 expression by Spearman’s correlation test. After serum starvation for 72 h, serum re-addition significantly increased the expression of LYAR, PCNA, and Cyclin A and promoted the cell cycle progression. LYAR knockdown inhibited the proliferation and induced the G0/G1 cell cycle arrest and apoptosis of A549 cells.
Conclusions. The present study revealed the clinical significance of LYAR in NSCLC. LYAR might serve as a
tumor promoter in NSCLC progression by promoting the proliferation and inhibiting the apoptosis of NSCLC
cells. Inhibiting the expression of LYAR was considered as a potential novel therapeutic strategy for NSCLC.
Abstract
Introduction. The aim of the study was to investigate the clinical significance of Ly-1 antibody reactive clone
(LYAR) in non-small-cell lung cancer (NSCLC).
Material and methods. The expressions of LYAR at the protein level in representative paired NSCLC tumor tissues and adjacent non-tumor tissues were measured by Western blot and immunohistochemistry. Kaplan-Meier method was used to calculate the survival curve of patients with NSCLC. Cell Counting Kit-8 assay and flow cytometry were used to estimate the cell proliferation and cell cycle, respectively. Terminal-deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay was performed to detect cell apoptosis.
Results. LYAR was dramatically overexpressed in NSCLC tissues which were closely related to the survival of patients with NSCLC. In clinical studies, the expression of LYAR was related to the clinical stage, histological differentiation, and Ki-67 expression. A positive correlation was found between LYAR and Ki-67 expression by Spearman’s correlation test. After serum starvation for 72 h, serum re-addition significantly increased the expression of LYAR, PCNA, and Cyclin A and promoted the cell cycle progression. LYAR knockdown inhibited the proliferation and induced the G0/G1 cell cycle arrest and apoptosis of A549 cells.
Conclusions. The present study revealed the clinical significance of LYAR in NSCLC. LYAR might serve as a
tumor promoter in NSCLC progression by promoting the proliferation and inhibiting the apoptosis of NSCLC
cells. Inhibiting the expression of LYAR was considered as a potential novel therapeutic strategy for NSCLC.
Keywords
non-small-cell lung cancer; Ly-1 antibody reactive clone; A549 cells; cell cycle; prognosis
About this articleTitle
LYAR promotes the proliferation of non-small cell lung cancer and is associated with poor prognosis
Journal
Folia Histochemica et Cytobiologica
Issue
Article type
Original paper
Pages
282-290
Published online
2021-12-10
Page views
6410
Article views/downloads
455
DOI
Pubmed
Bibliographic record
Folia Histochem Cytobiol 2021;59(4):282-290.
Keywords
non-small-cell lung cancer
Ly-1 antibody reactive clone
A549 cells
cell cycle
prognosis
Authors
Xiao-Ning Lu
Guan-Jun Ju
Yu-Xin Wang
Yong-Liang Wang
Kun Wang
Jian-Le Chen
Wei Cai
Qi-Wei Zang
References (21)- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1): 10–29.
- Yang Z, He J, Gao P, et al. miR-769-5p suppressed cell proliferation, migration and invasion by targeting TGFBR1 in non-small cell lung carcinoma. Oncotarget. 2017; 8(69): 113558–113570.
- Xu XL, Gong Y, Zhao DP. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 2018; 22(24): 8731–8739.
- Ou SHI, Zell JA, Ziogas A, et al. Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer. 2007; 110(7): 1532–1541.
- Cai J, Fang L, Huang Y, et al. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 2013; 73(17): 5402–5415.
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87–108.
- Kim IM, Ackerson T, Ramakrishna S, et al. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 2006; 66(4): 2153–2161.
- Su L, Hershberger RJ, Weissman IL. LYAR, a novel nucleolar protein with zinc finger DNA-binding motifs, is involved in cell growth regulation. Genes Dev. 1993; 7(5): 735–748.
- Swartling FJ, Grimmer MR, Hackett CS, et al. Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 2010; 24(10): 1059–1072.
- Wu Y, Liu M, Li Z, et al. LYAR promotes colorectal cancer cell mobility by activating galectin-1 expression. Oncotarget. 2015; 6(32): 32890–32901.
- Isaksson HS, Sorbe B, Nilsson TK. Whole genome expression profiling of blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14. Oncotarget. 2014; 5(12): 4040–4049.
- Kerr KM. Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification. J Clin Pathol. 2013; 66(10): 832–838.
- Lv L, Wan C, Chen B, et al. Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating WNT signaling pathway. J Cell Biochem. 2014; 115(1): 81–92.
- Xue Q, Lv L, Wan C, et al. Expression and clinical role of small glutamine-rich tetratricopeptide repeat (TPR)-containing protein alpha (SGTA) as a novel cell cycle protein in NSCLC. J Cancer Res Clin Oncol. 2013; 139(9): 1539–1549.
- Miyazawa N, Yoshikawa H, Magae S, et al. Human cell growth regulator Ly-1 antibody reactive homologue accelerates processing of preribosomal RNA. Genes Cells. 2014; 19(4): 273–286.
- Sun Y, Atmadibrata B, Yu D, et al. Upregulation of LYAR induces neuroblastoma cell proliferation and survival. Cell Death Differ. 2017; 24(9): 1645–1654.
- Ishibashi N, Maebayashi T, Aizawa T, et al. Correlation between the Ki-67 proliferation index and response to radiation therapy in small cell lung cancer. Radiat Oncol. 2017; 12(1): 16.
- Zhao WP, Wang HW, Liu J, et al. Positive PCNA and Ki-67 Expression in the Testis Correlates with Spermatogenesis Dysfunction in Fluoride-Treated Rats. Biol Trace Elem Res. 2018; 186(2): 489–497.
- Yonezawa K, Sugihara Y, Oshima K, et al. Lyar, a cell growth-regulating zinc finger protein, was identified to be associated with cytoplasmic ribosomes in male germ and cancer cells. Mol Cell Biochem. 2014; 395(1-2): 221–229.
- Abdelmohsen K, Gorospe M. RNA-binding protein nucleolin in disease. RNA Biol. 2012; 9(6): 799–808.
- Li H, Wang B, Yang A, et al. Ly-1 antibody reactive clone is an important nucleolar protein for control of self-renewal and differentiation in embryonic stem cells. Stem Cells. 2009; 27(6): 1244–1254.
